Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Aclaris Therapeutics announced positive Phase 1b results for its bispecific antibody ATI-052 targeting TSLP and IL-4Rα in atopic dermatitis and asthma. The drug demonstrated rapid and durable improvements in skin symptoms and itch in severe AD patients, with 78% achieving EASI-50 response. In asthma, a single dose produced rapid improvements in airway inflammation and lung function. The compound showed a favorable safety profile with no conjunctivitis observed. Aclaris plans to prioritize Phase 2b development in eosinophilic esophagitis (EoE) starting early 2027.